Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
Abstract The aim of this study was to evaluate the impact of renal impairment on the pharmacokinetics (PKs), safety, and tolerability of daridorexant, a dual orexin receptor antagonist intended for the treatment of insomnia. A single‐center, open‐label study evaluated the PKs of daridorexant in pati...
Guardado en:
Autores principales: | Benjamin Berger, Clemens Muehlan, Gernot Klein, Jasper Dingemanse |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fc8b4cfe396c4a1ebd06e4c57683c6a4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
por: Norman JL, et al.
Publicado: (2016) -
Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function.
por: Anna Jonsson Holmdahl, et al.
Publicado: (2021) -
Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function
por: Anna Jonsson Holmdahl, et al.
Publicado: (2021) -
Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8
por: Andreas Port, et al.
Publicado: (2021) -
Tumor cell apoptosis mediated by the orexins
por: A. S. Diatlova, et al.
Publicado: (2021)